Q-omics provides the consensus-scored SMIM32 profile across patient tissues and cancer cell-line models. SMIM32 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMIM32 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, SMIM32 RNA expression shows 12,350 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where SMIM32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM32 survival associations across molecular data types. SMIM32 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM32 RNA expression–survival associations across cancer types. High SMIM32 expression shows unfavorable associations in SKCM, UVM and BRCA, but favorable associations in KIRC, LGG and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMIM32 RNA expression.
This table summarizes SMIM32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM32 shows lower tumor expression in KICH, COAD and READ and higher tumor expression in LIHC, BRCA and LUSC. The KICH box plot shows higher SMIM32 RNA expression in normal versus tumor tissue (log2 FC = −4.995, t-test p < 0.001).
This table shows molecular features associated with SMIM32 in patient tissues and cancer cell lines. In patient samples, SMIM32 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
